Hædersdal, Sofie
Andersen, Andreas http://orcid.org/0000-0001-8190-5140
Knop, Filip K. http://orcid.org/0000-0002-2495-5034
Vilsbøll, Tina
Article History
Accepted: 17 February 2023
First Online: 17 March 2023
Competing interests
: S.H. has served as a consultant for Novo Nordisk. F.K.K. has served on scientific advisory panels, been part of speakers bureaus, served as a consultant to and/or received research support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gubra, MedImmune, MSD/Merck, Mundipharma, Norgine, Novo Nordisk, Sanofi, ShouTi, Zealand Pharma and Zucara, and is a minority shareholder in Antag Therapeutics. T.V. has served on scientific advisory panels, been part of speakers bureaus, and served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, Gilead, GSK, Mundipharma, MSD/Merck, Novo Nordisk, Sanofi and Sun Pharmaceuticals. A.A. has no competing interests.